Facharzt FMH Medizinische Onkologie Practice Questions - Facharzt FMH Für Medizinische Onkologie Spécialiste FMH En Oncologie Médicale Exam

Access More Questions

A 42-year-old premenopausal woman is diagnosed with clinical stage IIB (cT2 cN1 M0) triple-negative breast cancer (TNBC). Genetic testing is negative for germline BRCA1/2 mutations. In accordance with the KEYNOTE-522 trial and ESMO guidelines, what is the standard neoadjuvant and adjuvant treatment paradigm?

Neoadjuvant dose-dense AC followed by paclitaxel alone, followed by definitive surgery and adjuvant capecitabine for 8 cycles Neoadjuvant carboplatin plus paclitaxel followed by surgery, omitting anthracyclines and adjuvant therapy if a pathologic complete response is attained Neoadjuvant pembrolizumab monotherapy for 6 months followed by surgery and observation Neoadjuvant pembrolizumab combined with carboplatin/paclitaxel followed by doxorubicin/cyclophosphamide, then definitive surgery, followed by adjuvant pembrolizumab to complete 1 year

Correct Answer:

Neoadjuvant pembrolizumab combined with carboplatin/paclitaxel followed by doxorubicin/cyclophosphamide, then definitive surgery, followed by adjuvant pembrolizumab to complete 1 year

Access more questions from this quiz

Continue to Facharzt FMH Medizinische Onkologie Practice Questions - Facharzt FMH für Medizinische Onkologie Spécialiste FMH en oncologie médicale Exam for more practice questions and the full quiz experience.

Access More Questions